Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Biochem Cell Biol ; 84: 40-45, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-28065757

RESUMEN

Brain fatty acid (FA) metabolism deserves a close attention not only for its energetic aspects but also because FAs and their metabolites/derivatives are able to influence many neural functions, contributing to brain pathologies or representing potential targets for pharmacological and/or nutritional interventions. Glucose is the preferred energy substrate for the brain, whereas the role of FAs is more marginal. In conditions of decreased glucose supply, ketone bodies, mainly formed by FA oxidation, are the alternative main energy source. Ketogenic diets or medium-chain fatty acid supplementations were shown to produce therapeutic effects in several brain pathologies. Moreover, the positive effects exerted on brain functions by short-chain FAs and the consideration that they can be produced by intestinal flora metabolism contributed to the better understanding of the link between "gut-health" and "brain-health". Finally, attention was paid also to the regulatory role of essential polyunsaturated FAs and their derivatives on brain homeostasis.


Asunto(s)
Encéfalo/metabolismo , Ácidos Grasos/metabolismo , Animales , Dieta Cetogénica , Metabolismo Energético , Microbioma Gastrointestinal/fisiología , Glucosa/metabolismo , Homeostasis , Humanos , Cuerpos Cetónicos/metabolismo , Mitocondrias/metabolismo , Neuroprotección , Oxidación-Reducción , Peroxisomas/metabolismo , Transducción de Señal
2.
J Biotechnol ; 202: 31-9, 2015 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-25701681

RESUMEN

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the central nervous system. There are four clinical forms of MS, the most common of which is characterized by a relapsing remitting course (RRMS). The etiology of MS is unknown, but many studies suggested that genetic, environmental and infectious agents may contribute to the development of this disease. In experimental autoimmune encephalomyelitis (EAE), the animal model for MS, it has been shown that CD4(+) T cells play a key role in MS pathogenesis. In fact, these cells are able to cross the blood-brain barrier and cause axonal damage with neuronal death. T cell activation critically depends on mitochondrial ATP synthesis and reactive oxygen species (ROS) production. Interestingly, lots of studies linked the oxidative damage arising from mitochondrial changes to neurodegenerative disorders, such as MS. Based on these evidences, this work focused on the metabolic reprogramming of CD4(+) T cells in MS subjects, being this cell population directly implicated in pathogenesis of disease, paying attention to mitochondrial function and response to oxidative stress. Such aspects, once clarified, may open new opportunities for a therapeutic metabolic modulation of MS disorder.


Asunto(s)
Adenosina Trifosfato/metabolismo , Linfocitos T CD4-Positivos/metabolismo , Esclerosis Múltiple Recurrente-Remitente/inmunología , Oxidorreductasas/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mitocondrias/enzimología , Mitocondrias/patología , Esclerosis Múltiple Recurrente-Remitente/metabolismo , Esclerosis Múltiple Recurrente-Remitente/patología , Adulto Joven
3.
Free Radic Biol Med ; 73: 117-26, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24819445

RESUMEN

The accumulation of toxic hydrophobic bile acids in hepatocytes, observed during chronic cholestasis, induces substantial modification in the redox state and in mitochondrial functions. Recent reports have suggested a significant role of impaired lipid metabolism in the progression of chronic cholestasis. In this work we report that changes observed in the expression of the lipogenic enzymes acetyl-CoA carboxylase and fatty acid synthase were associated with a decrease in the activity of citrate carrier (CIC), a protein of the inner mitochondrial membrane closely related to hepatic lipogenesis. We also verified that the impairment of citrate transport was dependent on modification of the phospholipid composition of the mitochondrial membrane and on cardiolipin oxidation. Silybin, an extract of silymarin with antioxidant and anti-inflammatory properties, prevented mitochondrial reactive oxygen species (ROS) production, cardiolipin oxidation, and CIC failure in cirrhotic livers but did not affect the expression of lipogenic enzymes. Moreover, supplementation of silybin was also associated with mitochondrial biogenesis. In conclusion, we demonstrate that chronic cholestasis induces cardiolipin oxidation that in turn impairs mitochondrial function and further promotes ROS production. The capacity of silybin to limit mitochondrial failure is part of its hepatoprotective property.


Asunto(s)
Antioxidantes/uso terapéutico , Colestasis/patología , Cirrosis Hepática Biliar/patología , Recambio Mitocondrial/fisiología , Silimarina/uso terapéutico , Acetil-CoA Carboxilasa/biosíntesis , Animales , Antiinflamatorios/uso terapéutico , Transporte Biológico , Cardiolipinas/metabolismo , Proteínas Portadoras/metabolismo , Colestasis/tratamiento farmacológico , Ácido Cítrico/metabolismo , ADN Mitocondrial/genética , Activación Enzimática , Acido Graso Sintasa Tipo I/biosíntesis , Hepatocitos/metabolismo , Metabolismo de los Lípidos/fisiología , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática Biliar/tratamiento farmacológico , Masculino , Mitocondrias/metabolismo , Oxidación-Reducción , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma , Fosfolípidos/metabolismo , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Silibina , Factores de Transcripción/metabolismo
4.
Prostaglandins Other Lipid Mediat ; 99(3-4): 57-67, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23064030

RESUMEN

Chronic airway inflammation is a common symptom of several diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Excessive or inappropriate immune system activity and/or failure to resolve an acute inflammation spontaneously can induce functional changes in the walls and parenchyma of the airways. Continuous recruitment of inflammatory cells to the site of inflammation and the production of protein (i.e., cytokines, chemokines, enzymes, etc.) and lipid (eicosanoids) pro-inflammatory mediators contribute directly or indirectly to changes in airway structure and function. Pro-inflammatory eicosanoids are mainly formed by the metabolism of arachidonic acid, an n-6 polyunsaturated fatty acid esterified at the s-n2 position of membrane phospholipids. Unlike n-6 polyunsaturated fatty acids (PUFA), n-3 PUFA decrease inflammation. The anti-inflammatory effect of n-3 PUFA derives from their ability to compete with arachidonic acid in the production of eicosanoids, thereby decreasing the production of pro-inflammatory cytokines and reducing immune cell functions. Moreover, n-3 PUFA can give rise to a series of pro-resolving mediators with anti-inflammatory actions, such as resolvins and protectins. While most studies have reported n-3 PUFA to have beneficial effects on chronic airway diseases, some have questioned the anti-inflammatory effects of n-3 PUFA in inflammatory airway diseases. This paper summarizes the main mechanisms by which n-3 PUFA exert anti-inflammatory and pro-resolving effects, focusing on their use in airway disorders with an inflammatory component.


Asunto(s)
Asma/metabolismo , Fibrosis Quística/metabolismo , Ácidos Grasos Omega-3/farmacología , Inflamación/metabolismo , Enfermedad Pulmonar Obstructiva Crónica/metabolismo , Sistema Respiratorio/efectos de los fármacos , Animales , Ácido Araquidónico/metabolismo , Asma/fisiopatología , Antígenos CD59/metabolismo , Quimiocinas/metabolismo , Enfermedad Crónica , Fibrosis Quística/fisiopatología , Ácidos Docosahexaenoicos/metabolismo , Eicosanoides/metabolismo , Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-6/metabolismo , Humanos , Inflamación/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Sistema Respiratorio/metabolismo , Sistema Respiratorio/fisiopatología
5.
PLoS One ; 7(6): e38797, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22685607

RESUMEN

Krill oil (KO) is a dietary source of n-3 polyunsaturated fatty acids, mainly represented by eicosapentaenoic acid and docosahexaenoic acid bound to phospholipids. The supplementation of a high-fat diet with 2.5% KO efficiently prevented triglyceride and cholesterol accumulation in liver of treated rats. This effect was accompanied by a parallel reduction of the plasma levels of triglycerides and glucose and by the prevention of a plasma insulin increase. The investigation of the molecular mechanisms of KO action in high-fat fed animals revealed a strong decrease in the activities of the mitochondrial citrate carrier and of the cytosolic acetyl-CoA carboxylase and fatty acid synthetase, which are both involved in hepatic de novo lipogenesis. In these animals a significant increase in the activity of carnitine palmitoyl-transferase I and in the levels of carnitine was also observed, suggesting a concomitant stimulation of hepatic fatty acid oxidation. The KO supplemented animals also retained an efficient mitochondrial oxidative phosphorylation, most probably as a consequence of a KO-induced arrest of the uncoupling effects of a high-fat diet. Lastly, the KO supplementation prevented an increase in body weight, as well as oxidative damage of lipids and proteins, which is often found in high-fat fed animals.


Asunto(s)
Suplementos Dietéticos , Euphausiacea/química , Hígado Graso/prevención & control , Aceites/farmacología , Acetil-CoA Carboxilasa/metabolismo , Animales , Western Blotting , Peso Corporal/efectos de los fármacos , Carnitina O-Palmitoiltransferasa/metabolismo , Proteínas Portadoras/metabolismo , Dieta Alta en Grasa/efectos adversos , Ingestión de Alimentos/efectos de los fármacos , Ácido Graso Sintasas/metabolismo , Ácidos Grasos/biosíntesis , Ácidos Grasos Omega-3/biosíntesis , Ácidos Grasos Omega-3/química , Ácidos Grasos Omega-3/farmacología , Hígado Graso/sangre , Hígado Graso/etiología , Lípidos/análisis , Lípidos/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Aceites/química , Tamaño de los Órganos/efectos de los fármacos , Oxidación-Reducción/efectos de los fármacos , Fosforilación Oxidativa/efectos de los fármacos , Ratas , Ratas Sprague-Dawley
6.
J Lipid Res ; 44(11): 2135-41, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14634051

RESUMEN

The mitochondrial tricarboxylate carrier (TCC) plays an important role in lipogenesis being TCC-responsible for the efflux from the mitochondria to the cytosol of acetyl-CoA, the primer for fatty acid synthesis. In this study, we investigated the effects of two high-fat diets with different fatty acid composition on the hepatic TCC activity. Rats were fed for 3 weeks on a basal diet supplemented with 15% of either coconut oil (CO), abundant in medium-chain saturated fatty acids, or fish oil (FO), rich in n-3 polyunsaturated fatty acids. Mitochondrial fatty acid composition was differently influenced by the dietary treatments, while no appreciable change in phospholipid composition and cholesterol level was observed. Compared with CO, the TCC activity was markedly decreased in liver mitochondria from FO-fed rats; kinetic analysis of the carrier revealed a decrease of the Vmax, with no change of the Km. No difference in the Arrhenius plot between the two groups was observed. Interestingly, the carrier protein level and the corresponding mRNA abundance decreased following FO treatment. These data indicate that FO administration markedly decreased the TCC activity as compared with CO. This effect is most likely due to a reduced gene expression of the carrier protein.


Asunto(s)
Proteínas Portadoras/metabolismo , Grasas de la Dieta/farmacología , Aceites de Pescado/farmacología , Mitocondrias Hepáticas/efectos de los fármacos , Mitocondrias Hepáticas/metabolismo , Aceites de Plantas/farmacología , Animales , Transporte Biológico/efectos de los fármacos , Colesterol/metabolismo , Ácido Cítrico/metabolismo , Ácido Cítrico/farmacología , Aceite de Coco , Grasas de la Dieta/administración & dosificación , Aceites de Pescado/administración & dosificación , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Cinética , Masculino , Fosfolípidos/metabolismo , Aceites de Plantas/administración & dosificación , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA